Skip to main content
SpringerLink
Log in

Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer

  • Chapter
  • First Online:
Lung Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 2197 Accesses

Abstract

While advanced non-small cell lung cancer often responds to chemotherapy, it eventually develops resistance and remains incurable. Recent studies indicate that each of docetaxel, pemetrexed, and the epidermal growth factor receptor inhibitor erlotinib may prolong survival and improve quality of life for some patients with tumor progression during or after front-line chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fossella FV, Lee JS, Murphy WK et al (1994) Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12:1238

    PubMed  CAS  Google Scholar 

  2. Francis PA, Rigas JR, Kris MG et al (1994) Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12:1232

    PubMed  CAS  Google Scholar 

  3. Cerny T, Kaplan S, Pavlidis N et al (1994) Docetaxel (Docetaxel) is active in non-small cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 70:384

    Article  PubMed  CAS  Google Scholar 

  4. Burris HA, Eckardt J, Fields S et al (1993) Phase II trials of Docetaxel in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 12:335 (abstract)

    Google Scholar 

  5. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of. Docetaxel versus best supportive care in patients with non-small cell lung cancer patients previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095

    PubMed  CAS  Google Scholar 

  6. Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 18:2354

    PubMed  CAS  Google Scholar 

  7. Shepherd FA, Fossella FV, Lynch T et al (2001) Docetaxel (Docetaxel) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol 28(Suppl 2):4-9

    PubMed  CAS  Google Scholar 

  8. Fossella FV, DeVore R, Kerr RN et al (2001) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol Classic Papers and Current Comments 6:97

    Google Scholar 

  9. Clarke S, Boyer M, Millward M et al (1997) Phase II study of LY231514, a multitargeted antifolate, in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 16:465a (abstract 1670)

    Google Scholar 

  10. Rusthoven J, Eisenhauer E, Butts C et al (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study - National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194-1199

    PubMed  CAS  Google Scholar 

  11. Smit E, Mattson K, von Pawel J et al (2003) Alimta (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: a phase II study. Ann Oncol 14:455-460

    Article  PubMed  CAS  Google Scholar 

  12. Vogelzang N, Rusthoven J, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644

    Article  PubMed  CAS  Google Scholar 

  13. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597

    Article  PubMed  CAS  Google Scholar 

  14. Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4:397-406

    Article  PubMed  CAS  Google Scholar 

  15. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246

    Article  PubMed  CAS  Google Scholar 

  16. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158

    Article  PubMed  CAS  Google Scholar 

  17. Perez-Soler R, Chachoua A, Hammond LA et al (2004) Determination of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 22:3238-3247

    Article  PubMed  CAS  Google Scholar 

  18. Shepherd FA, Pereira JR, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 353:123-132

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 432, Houston, TX, 77030, USA

    Frank V. Fossella

Authors
  1. Frank V. Fossella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank V. Fossella .

Editor information

Editors and Affiliations

  1. M. D. Anderson Cancer Center, University of Texas, Holcombe Blvd. 1515, Houston, 77030, U.S.A.

    David J. Stewart

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Fossella, F.V. (2010). Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer. In: Stewart, D. (eds) Lung Cancer. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-524-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-524-8_9

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-523-1

  • Online ISBN: 978-1-60761-524-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation